A pilot study of the plasma and urinary neurotransmitters in Chinese children with autism spectrum disorder.
Xin Yingying, Yang Yifan, Qian Qiaoqiao, Xia Ting, Zhang Wanqing, Dai Taoying, Li Ruizhen, Liu Zhisheng, Zhang Chuanjie
What this study means for families
Researchers compared blood and urine levels of brain chemicals (neurotransmitters) in children with autism versus typically developing children. They found several differences - some chemicals were higher in autistic children, others were lower. Importantly, certain chemical levels seemed to relate to how severe a child's autism symptoms were. This suggests these chemicals might help doctors better understand and assess autism severity, though more research is needed.
Summary by AutismInsights from published abstract. This is not a substitute for reading the original paper.
Research summary
This pilot study examined plasma and urinary neurotransmitter levels in Chinese children with autism spectrum disorder (ASD) compared to typically developing children. The study found significant differences in multiple neurotransmitters between groups, with plasma GABA levels negatively correlating with autism severity scores, while urinary norepinephrine and normetanephrine levels positively correlated with severity. Plasma dopamine, normetanephrine, serotonin, and GABA were elevated in ASD children, while plasma norepinephrine and tyrosine were reduced. The findings suggest peripheral neurotransmitter levels may serve as potential auxiliary biomarkers for assessing autism severity, though larger validation studies are needed.
Summary by AutismInsights from published abstract. This is not a substitute for reading the original paper.
Key findings
- 1
Plasma GABA levels were negatively associated with autism severity scores
Confidence: moderateRelevance: May serve as biomarker for assessing autism severity - 2
Urinary norepinephrine and normetanephrine levels positively correlated with autism severity
Confidence: moderateRelevance: Potential auxiliary biomarkers for severity assessment - 3
Multiple neurotransmitter differences found between ASD and typically developing children
Confidence: moderateRelevance: Suggests peripheral neurotransmitter disruption in autism
Summary by AutismInsights from published abstract. This is not a substitute for reading the original paper.
Clinical implications
Peripheral neurotransmitter levels may serve as auxiliary biomarkers for autism severity assessment. However, clinical application requires validation in larger, diverse populations. The findings suggest potential for developing biochemical tools to complement existing autism diagnostic and severity assessment methods.
Summary by AutismInsights from published abstract. This is not a substitute for reading the original paper.
Limitations
Pilot study with small sample size (40 controls mentioned, ASD sample size unclear). Single population (Chinese children). Cross-sectional design limits causal inferences. Authors explicitly note need for larger validation studies.
Summary by AutismInsights from published abstract. This is not a substitute for reading the original paper.
Original abstract
Recent studies have indicated that there are imbalances in neurotransmitter levels in children with autism spectrum disorder (ASD). Alterations in peripheral blood and urinary neurotransmitter levels may serve as biomarkers for ASD. This study aims to explore the relationship between neurotransmitter levels and the severity of ASD. Totally, forty sex-, age-, and ethnically matched typically developing (TD) children were recruited to compare the neurotransmitter levels with ASD aged over 3 years.
Differences in plasma and urinary neurotransmitter levels between TD children and children with ASD were compared using the Mann-Whitney U test. For the indicators that showed significant differences, further multivariate regression analysis was conducted to assess the association between individual neurotransmitters and Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) Calibrated Severity Score (CSS). Finally, a restricted cubic spline (RCS) model was applied to explore the dose-response relationship between neurotransmitter concentrations and ADOS-2 CSS. Plasma levels of dopamine (DA), normetanephrine (NMN), 5-hydroxytryptamine (5-HT), γ-aminobutyric acid (γ-GABA) levels in ASD were significantly higher than those in TD children while plasma levels of norepinephrine (NE), tyrosine (Tyr) were significantly lower.
Urinary levels of NMN were significantly lower, while epinephrine (E), NE, vanillylmandelic acid (VMA), homovanillic acid (HVA) were significantly higher in children with ASD compared to TD. After adjusting for confounders of age, sex and BMI, plasma GABA was negatively associated with ADOS-2 CSS, while urinary NE and NMN were positively associated with ADOS severity scores (P < 0.05). Multiple regression analysis indicated that plasma GABA and urinary NE and NMN levels explained 26.9%, 24.8% and 15.8% of the variability in ADOS-2 CSS for ASD. The RCS analysis results were largely consistent with the linear regression analysis results.
Plasma GABA and urinary NE, and NMN exhibited a linear correlation with ADOS-2 CSS. Plasma NE and Tyr showed a U-shaped curve relationship with the ADOS-2 CSS (P< 0.05). A significant negative correlation was observed between plasma GABA neurotransmitter concentrations and ASD severity. In contrast, NE and NMN levels in urine showed significantly positive correlations with ASD severity.
Both excessively low and excessively high plasma NE and Tyr levels may be associated with more severe autism symptoms, suggesting a disruption in peripheral neurotransmitter levels in children with ASD. Future studies with larger sample sizes are required for prediction and validation. The peripheral neurotransmitters may serve as potential auxiliary biomarkers for assessing the severity of autism.
Evidence Grade
emerging
Grade assigned by AutismInsights based on study type and published abstract.
Study Details
- Journal
- BMC psychiatry
- Year
- 2025
- PMID
- 41423608
- DOI
- 10.1186/s12888-025-07682-7
MeSH Terms